Making the case for the development of a vaccination against hepatitis E virus

Hepatitis E virus (HEV) infection is a global problem that affects 20 million individuals, and cause acute hepatitis in 3.5 million, with approximately 70 000 deaths worldwide per year. While the acute disease is generally self‐limited, however, it may progress to fatal fulminant liver failure in ce...

Full description

Saved in:
Bibliographic Details
Published in:Liver international 2015-02, Vol.35 (2), p.311-316
Main Authors: Haffar, Samir, Bazerbachi, Fateh, Lake, John R.
Format: Article
Language:English
Subjects:
Clinical Trials as Topic
Genome, Viral - genetics
Genotype
Hepatitis E - epidemiology
Hepatitis E - prevention & control
hepatitis E virus (HEV)
Hepatitis E virus - drug effects
Hepatitis E virus - genetics
HEV vaccine
Humans
primary prevention
vaccination
viral hepatitis
Viral Hepatitis Vaccines - pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hepatitis E virus (HEV) infection is a global problem that affects 20 million individuals, and cause acute hepatitis in 3.5 million, with approximately 70 000 deaths worldwide per year. While the acute disease is generally self‐limited, however, it may progress to fatal fulminant liver failure in certain individuals. Contaminated water supplies disseminate this virus through the faecal–oral route, and swine is thought to be its zoonotic reservoir. Attempts have been made to develop effective HEV vaccines, and two candidates have undergone successful clinical trials. In this review, we discuss HEV epidemiology, genotypes, microbiological structure, as well as the most recent advances in vaccination developments.
ISSN:1478-3223
1478-3231
DOI:10.1111/liv.12590